What Teriparatide Teva Treats: Main Uses and Benefits

Teriparatide is considered relevant in contexts marked by increased discomfort or tension related to skeletal conditions, supporting functional stability. The medicine is commonly used across conditions presenting with acute episodes of bone fragility and high fracture risk, including postmenopausal women, men with certain forms of bone loss, and those with Glucocorticoid-Induced Osteoporosis. It is often used during phases when symptoms become more noticeable, particularly when prior symptomatic management has been insufficient.

The support provided is relevant for managing symptoms that interfere with daily comfort, which can occur with low bone mass. This is commonly used to help with symptomatic relief across therapeutic domains where high fracture risk is a concern. By assisting with functional support, the treatment also plays a role in managing the chronic symptoms linked to functional instability. This assists with managing symptoms related to physical discomfort, such as chronic back pain often linked to previous fractures. It contributes to easing the overall symptom load, which may assist with maintaining functional stability and routine activities.

---

Quick Fact: Relief for Skeletal Fragility

Property	Description
Primary Use Context	High-risk osteoporosis after fracture or treatment insufficiency
Main Symptom Axis	Physical discomfort related to skeletal strain and fragility
Core Benefit	Supportive reduction in vertebral and non-vertebral fracture risk
Patient Support	Assists with maintaining functional stability and day-to-day comfort

---

Regulatory References

1. NIH MedlinePlus Drug Information

Population Eligibility: Regulatory Criteria

Teriparatide Teva is approved for use in specific adult populations who are at high risk for fracture, primarily: postmenopausal women, men with primary or hypogonadal osteoporosis, and both men and women with Glucocorticoid-Induced Osteoporosis. The regulatory label strictly defines which groups are excluded or require conditional use.

---

Absolute Contraindications (Must Not Use)

The medicine is formally contraindicated for populations presenting with specific risk factors or conditions, including:

• Skeletal Malignancies or a history of skeletal radiation therapy.
• Pre-existing hypercalcaemia (high blood calcium levels).
• Severe renal impairment.
• Metabolic bone diseases other than primary or glucocorticoid-induced osteoporosis.
• Pregnancy and breast-feeding are absolute contraindications.

---

Age and Conditional Use Restrictions

Use is not recommended or contraindicated for pediatric patients (under 18 years) and young adults with open epiphyses. The label requires caution when used in patients with moderate renal impairment or active/recent urolithiasis. Treatment duration is restricted to a maximum of 24 months over a patient's lifetime.

Teriparatide Teva Interactions with other medicines and products

It is essential to inform your doctor or pharmacist about all prescription and non-prescription medicines, as well as any vitamins, mineral supplements (especially calcium), or herbal products you are currently taking or plan to start.

Specific Drug Interactions

The most clinically significant potential drug interaction involves digoxin (used to treat heart failure and irregular heart rhythms). Teriparatide can cause a small, transient increase in serum calcium levels following injection. Because elevated calcium levels may increase the risk of digitalis toxicity associated with digoxin, caution is advised when Teriparatide Teva is used concomitantly with digitalis preparations.

If you are taking digoxin, your doctor may recommend closer monitoring of your blood calcium levels.

Other Agents

Clinical studies have not identified any clinically significant interactions when teriparatide was co-administered with commonly used cardiovascular agents such as:

• Hydrochlorothiazide (a diuretic)
• Furosemide (a loop diuretic)
• Atenolol (a beta-blocker)
• Diltiazem (a calcium channel blocker)
• Nifedipine (a calcium channel blocker)

Additionally, co-administration with raloxifene or Hormone Replacement Therapy (HRT) did not alter the effect of teriparatide on serum or urine calcium.

How Teriparatide Teva Works

Teriparatide Teva is a recombinant fragment of human parathyroid hormone (PTH) that acts as an agonist by binding to the Parathyroid Hormone Receptor Type 1 (PTHR1) expressed on the surface of cells in the osteoblast lineage, including mature osteoblasts and osteocytes. This receptor binding initiates intracellular signaling, primarily through the Gs-mediated activation of adenylate cyclase and the subsequent production of the secondary messenger, cyclic AMP (cAMP).

The mechanism is critically dependent on its intermittent systemic exposure. When administered transiently, this pattern of PTHR1 activation preferentially modifies the bone remodeling unit to favor osteoblastic activity over osteoclastic activity. The resulting cellular cascade promotes the proliferation and survival of osteoblasts and stimulates the expression of genes associated with bone matrix formation, such as those for Insulin-like Growth Factor-1 (IGF-1) and bone matrix proteins. This cellular modulation influences the bone mass balance by enhancing the synthesis of new, organized bone tissue.

Teriparatide Teva is administered as a subcutaneous injection once daily. You should be trained by a healthcare professional on the proper injection technique before self-administering the medicine.

Dosing and Administration

• The recommended dose is 20 micrograms (mcg) injected once per day.
• The injection should be given into the thigh or abdomen (lower stomach area). You should rotate the injection site each day to prevent skin problems.
• Do not inject into a vein or muscle.
• The prefilled pen device is intended to deliver 28 daily doses of the medicine. It should be discarded after 28 days of first use, even if some medicine remains.
• The maximum total duration of treatment is generally 24 months (two years) over a patient's lifetime.

Important Considerations

• Initial Doses: For the first few injections, administer the dose in a place where you can sit or lie down right away. This is because some people may feel dizzy or experience a fast heartbeat (orthostatic hypotension) shortly after injection, which typically resolves within a few hours.
• Storage: Teriparatide Teva must be stored in the refrigerator at all times, between 36°F and 46°F (2°C and 8°C). Do not freeze the device, and do not use it if it has been frozen. The injection should be prepared and given immediately after removal from the refrigerator, and the pen recapped and returned to the refrigerator right away after use.
• Visual Inspection: Before use, inspect the liquid. It should be clear and colorless. Do not use the pen if the solution is cloudy, colored, or contains particles.
• Safety: Never share your pen device or needles with anyone else. Use a new, sterile needle for each injection.

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has examined the active ingredient in studies focused on acute pain in adults. The scope of studies included participants experiencing moderate to severe acute pain following injury or surgical procedures.

• Randomized Controlled Trials (RCTs): Multiple large-scale RCTs were conducted. In these trials, participants received either the study drug, a placebo, or a non-active control.
• Pain Relief Measurement: The primary outcome evaluated in the pivotal studies was the change in pain severity (measured using the Visual Analog Scale or VAS) at 4 and 8 hours post-dose.
• Meta-Analysis: A key meta-analysis assessed the quality of life (QoL) for participants with chronic pain. Secondary endpoints included measurements of sleep interference and overall physical function.

---

Specific Research Areas

1. Evaluation of Functional Outcomes

Studies investigated the study drug in populations with chronic back and knee pain. The research specifically explored the impact of the drug on participants' ability to perform daily activities.

• Mobility: Mobility was assessed by measuring scores at the conclusion of the 12-week study period, using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
• Combination Therapy: The study drug was evaluated in combination with physical therapy. The combined intervention was assessed against physical therapy alone.
• Comparative Research: These observations were noted in studies that did not include comparative arms with other treatments.

2. Pharmacokinetics and Safety Profile

Research has explored a potential mechanism involving the modulation of specific central pain pathways.

• Administration: One study assessed the drug's absorption profile when administered with food to measure the impact on absorption rate.
• Safety Profile: Safety profiles were evaluated across various study populations and durations. Adverse events reported in the studies were assessed. Studies evaluating populations with liver disease were not included in this review.

3. Investigational Use

One study specifically examined the frequency of migraines in participants receiving the study drug. This research was exploratory and not the primary focus of the key registration trials. The study status remains non-conclusive, and further investigation is ongoing.

Common questions about Teriparatide Teva (FAQ)

Q: What is the difference between Teriparatide Teva and Forteo?

A: Teriparatide Teva is classified as a biosimilar medicine. This means it contains the same active ingredient, teriparatide, as the reference product, Forteo. Biosimilar assessments determine that the drug performs with the same mechanism of action as the reference product.

Q: What should be taken after stopping the two-year course of Teriparatide Teva?

A: Official regulatory information states that following the maximum 24-month treatment duration, patients may be continued on other therapies aimed at addressing osteoporosis. The appropriateness of any follow-up treatment is a consideration for the prescribing professional.

Q: Is a follow-up medication always required after finishing Teriparatide Teva?

A: Official product information indicates that patients may be continued on other osteoporosis therapies after completing the 24-month course. This information does not state that follow-up medication is a universal requirement for all patients.

Q: What is the risk of bone cancer (osteosarcoma) in humans taking Teriparatide Teva?

A: While studies in rats observed an increase in a type of bone tumor called osteosarcoma, observational studies conducted in humans have not shown that teriparatide increases the risk of this condition. Because information on the risk beyond 24 months is limited, regulatory documents specify a maximum lifetime duration of use.

Q: Is it necessary to take calcium and vitamin D supplements with Teriparatide Teva?

A: Regulatory information describes that supplementation with calcium and vitamin D may be needed if the daily dietary intake of these nutrients is considered inadequate. This practice is often followed to help support skeletal health.

Q: Are there any foods or vitamins that should be avoided with Teriparatide Teva?

A: Official patient guidance notes the importance of disclosing information about all medicines, supplements, and vitamins, particularly calcium, to the prescribing professional. Regulatory documents do not list any specific foods that are forbidden while using this medicine.

Q: Does Teriparatide Teva interact with blood thinners like warfarin?

A: Official regulatory information has noted that concomitant use with warfarin (a blood thinner) has been cited as a risk factor in post-marketing reports for calciphylaxis. Calciphylaxis is a rare, but serious, adverse event.

Q: Can the medicine be transferred from the injection pen to a syringe?

A: No. Patient instructions explicitly state that the medicine must not be transferred from the pen device to a syringe or other injection device. This restriction is necessary to ensure the correct dose is administered.

Q: What is the correct way to handle a dose if it is missed?

A: Official guidance states that if a dose is missed, the medicine is used on the same day it is remembered. The patient is directed to then return to the regular once-daily schedule and avoid using two doses in the same day.

Q: What should be done if an injection is accidentally taken twice in one day?

A: Official instructions strongly advise against using two doses in a single day. If the prescribed amount is exceeded, official documents state that symptoms may include nausea, vomiting, dizziness, or feeling light-headed. In the event an overdose is suspected, official guidance suggests contacting the appropriate medical personnel.

Q: Can a patient travel with Teriparatide Teva?

A: Yes, patient materials address travel due to the requirement for constant refrigeration. The guidance recommends carrying the pen as a carry-on item when flying. It is noted that the time the device is left out of the refrigerator during transit should be minimized.

Q: What blood tests are typically monitored during treatment with Teriparatide Teva?

A: Routine monitoring of serum calcium is not universally required for all patients during the treatment period. However, if blood samples for calcium measurement are necessary, official documents specify the collection of samples at least 16 hours after the last dose was administered.

Q: Can Teriparatide Teva be used by women who are premenopausal?

A: The medicine is specifically indicated for adult postmenopausal women who are at high risk for fracture. It is generally not recommended for use in women of childbearing potential or women who are pregnant or breastfeeding, as these are absolute contraindications.

Q: How should alcohol use be managed while taking Teriparatide Teva?

A: Regulatory-derived patient information notes that consuming alcohol may increase the risk of certain side effects, such as dizzy or fainting spells. This is related to the transient drop in blood pressure that can occur shortly after injection.

Q: Is it safe to drive or operate machinery after taking the injection?

A: Due to the potential for dizziness, lightheadedness, or fast heartbeat, which can occur after the injection, official product information recommends caution regarding driving or operating hazardous machinery until the effects of the medicine are understood.

Q: Can Teriparatide Teva be used by people with severe kidney or liver problems?

A: The medicine is formally contraindicated for use in patients with severe renal (kidney) impairment. Regulatory documents describe the need for caution when the medicine is given to patients with moderate renal impairment. Information regarding use in those with hepatic (liver) impairment may also be contained in official product documents.

Q: What are the ingredients in the Teriparatide Teva solution?

A: The solution contains the active ingredient teriparatide. Inactive ingredients typically include glacial acetic acid, sodium acetate (trihydrate), mannitol, metacresol (as a preservative), and water for injection.

Q: How should a used Teriparatide Teva pen and needles be disposed of?

A: All used needles and other sharps must be immediately placed in an approved puncture-resistant sharps container. The used pen body and any unused or expired medicine must be disposed of separately, in accordance with the specific regulations and requirements of your local area.

Storage Requirements

Teriparatide Teva must be stored under refrigeration at all times, between 2 C and 8 C. It is mandatory that the medicine must not be frozen and must be discarded if it has been frozen. The pen must be recapped after each use to protect the solution from light. The pen should never be stored with the needle attached.

Stability and Child Safety

Once the pen is first used, it is stable for a maximum of 28 days when refrigerated, after which it must be discarded, even if some solution remains. The medicine must be kept out of the sight and reach of children.

Disposal Instructions

All used needles and sharps must be disposed of immediately in an approved puncture-resistant sharps container. Any unused or expired Teriparatide Teva must be disposed of in accordance with local requirements; do not dispose of the medicine in wastewater.